BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29449224)

  • 1. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.
    Mastaglio S; Wong E; Perera T; Ripley J; Blombery P; Smyth MJ; Koldej R; Ritchie D
    Blood Adv; 2018 Feb; 2(4):335-346. PubMed ID: 29449224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
    Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
    Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients.
    Sanchez-Correa B; Gayoso I; Bergua JM; Casado JG; Morgado S; Solana R; Tarazona R
    Immunol Cell Biol; 2012 Jan; 90(1):109-15. PubMed ID: 21383766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.
    Stringaris K; Sekine T; Khoder A; Alsuliman A; Razzaghi B; Sargeant R; Pavlu J; Brisley G; de Lavallade H; Sarvaria A; Marin D; Mielke S; Apperley JF; Shpall EJ; Barrett AJ; Rezvani K
    Haematologica; 2014 May; 99(5):836-47. PubMed ID: 24488563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
    Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
    Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients.
    Maat W; van der Slik AR; Verhoeven DH; Alizadeh BZ; Ly LV; Verduijn W; Luyten GP; Mulder A; van Hall T; Koning F; Jager MJ; van Bergen J
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2888-95. PubMed ID: 19234348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion.
    Khaznadar Z; Boissel N; Agaugué S; Henry G; Cheok M; Vignon M; Geromin D; Cayuela JM; Castaigne S; Pautas C; Raffoux E; Lachuer J; Sigaux F; Preudhomme C; Dombret H; Dulphy N; Toubert A
    J Immunol; 2015 Sep; 195(6):2580-90. PubMed ID: 26246143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell receptor repertoire is comparable amongst newly diagnosed acute myeloid leukemia of different French-American-British subtypes, risk categories and chemosensitivities.
    Ho X; Fook-Chong S; Linn YC
    Leuk Lymphoma; 2014 Feb; 55(2):342-8. PubMed ID: 23550989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.
    Sanchez-Correa B; Morgado S; Gayoso I; Bergua JM; Casado JG; Arcos MJ; Bengochea ML; Duran E; Solana R; Tarazona R
    Cancer Immunol Immunother; 2011 Aug; 60(8):1195-205. PubMed ID: 21644031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.
    Kaito Y; Sugimoto E; Nakamura F; Tsukune Y; Sasaki M; Yui S; Yamaguchi H; Goyama S; Nannya Y; Mitani K; Tamura H; Imai Y
    Haematologica; 2024 Apr; 109(4):1107-1120. PubMed ID: 37731380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
    Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
    Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.
    Kearney CJ; Ramsbottom KM; Voskoboinik I; Darcy PK; Oliaro J
    Oncoimmunology; 2016 Aug; 5(8):e1196308. PubMed ID: 27622064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome.
    Herst PM; Howman RA; Neeson PJ; Berridge MV; Ritchie DS
    J Leukoc Biol; 2011 Jan; 89(1):51-5. PubMed ID: 20959411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
    Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
    Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
    Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
    Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.
    Schlegel P; Ditthard K; Lang P; Mezger M; Michaelis S; Handgretinger R; Pfeiffer M
    J Immunol Res; 2015; 2015():473175. PubMed ID: 26236752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
    Shimoni A; Vago L; Bernardi M; Yerushalmi R; Peccatori J; Greco R; Shem-Tov N; Lo Russo A; Danylesko I; Apel A; Bonini C; Lupo Stanghellini MT; Nagler A; Ciceri F
    Am J Hematol; 2017 Oct; 92(10):1011-1019. PubMed ID: 28631269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression analysis of activating and inhibitory receptors of natural killer cells in patients with acute myeloblastic leukemia.
    Ghasemimehr N; Moazed V; Fatemi A
    Adv Med Sci; 2020 Sep; 65(2):354-360. PubMed ID: 32592956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.